The emergence of medications like copyright and Semaglutide signifies a remarkable shift in how we manage type 2 diabetes. These innovative therapies belong to a class known as GLP-1 receptor agonists, which duplicate the effects of a natural hormone that regulates blood sugar levels and appetite